Status and Updates
April 22, 2020: The FTC informs the NARB that it was closing out its investigation without enforcement action.
January 13, 2020: The NARB refers advertising claims made by Neurocore to the FTC for review after the NARB concluded that the company did not comply with NARB’s recommendations.
November 12, 2019: After its own investigation, TINA.org files complaint letters with the FTC and FDA against Neurocore urging both agencies to take appropriate enforcement action.
June 4, 2018: The National Advertising Review Board (NARB) panel affirms NAD’s decision.
August 9, 2017: The National Advertising Division (NAD) recommends that Neurocore discontinue certain advertising claims for the company’s “Brain Training Centers,” including claims related to Attention Deficit/Hyperactivity Disorder (ADHD), autism, migraines, memory issues, sleep disorders and stress.
Related Posts
Prevagen Dietary Supplements →
Quincy Bioscience’s Prevagen →
Prevagen Products →
